Not Yet RecruitingPhase 3

Comparison Between Intrathecal Magnesium Sulphate & Dexmedetomidine in DHS

92 participantsStarted 2026-02-01

Plain-language summary

To compare the efficacy and safety of intrathecal dexmedetomidine and magnesium sulphate as adjuvants to 0.5% hyperbaric bupivacaine in patients undergoing elective DHS fixation, focusing on onset and duration of sensory and motor block, hemodynamic stability, and quality of postoperative analgesia.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 18-65 year * ASA Physical Status I or II * Scheduled for elective DHS fixation under spinal anesthesia * Written informed consent provided * Patients of both sex are included in the study. Exclusion Criteria: * Patient refusal * Allergy to study drugs * Local infection at injection site * Neurological or psychiatric illness * Coagulopathy * Chronic opioid or sedative use

What they're measuring

Highest Dermatome Level of Sensory Block

Timeframe: 24 hours after intervention

Duration of postoperative analgesia

Timeframe: 24 hours after intervention

Degree of Motor Block

Timeframe: 24 hours after intervention

Trial details

NCT IDNCT07326397

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11-01

View on ClinicalTrials.gov More Effects of Dexmedetomidine & Magnesium Sulphate on Patients Undergoing DHS trials